Sterling/Yamanouchi joint venture
Executive Summary
Sterling's joint venture with the Japanese firm, to be known as Sterling-Yamanouchi, will commercialize Sterling's ethical drugs in Japan. Under the agreement, Yamanouchi will be the exclusive distributor of the joint venture's products in Japan. The venture, which is subject to Japanese regulatory approval, will be co-owned by Sterling (51%) and Yamanouchi (49%). Sterling said its existing licenses in Japan will remain intact and its OTC and consumer products will continue to be marketed through Sterling-Winthrop.